DOCTOR PROFILE
Dr. Pierre Krystkowiak is a Senior Consultant Neurologist with more than 20 years of experience in the diagnosis and management of complex neurological disorders. Since joining the Specialized Rehabilitation Hospital (SRH), Abu Dhabi, he has brought extensive clinical and academic expertise to the care of patients requiring specialised neurological evaluation and treatment.
Dr. Krystkowiak has expertise in movement disorders, including Parkinson’s disease and related syndromes. He is experienced in advanced therapeutic interventions such as deep brain stimulation, apomorphine pump therapy, and Duodopa pump treatment. His clinical scope also includes the management of stroke, epilepsy, Alzheimer’s disease, and other neurological conditions that require multidisciplinary care.
An academic neurologist and PhD scientist, Dr. Krystkowiak has published 147 articles in international peer reviewed journals, including the most prestigious journals such as The New England Journal of Medicine and the Lancet Neurology. His approach combines evidence-based neurological care with collaborative treatment planning to support comprehensive patient management and long-term functional outcomes.
AREAS OF CLINICAL EXPERTISE
ACADEMIC DISTINCTIONS
MD IN NEUROLOGY
University of Lile, France 1997
PHD IN BIOMECHANICS
University of Paris-Saclay 2003
CAREER HIGHLIGHTS
Senior Consultant Neurologist,
Specialized Rehabilitation Hospital (SRH), Abu Dhabi
September 2025 – Present
Senior Consultant Neurologist,
Professor of Neurology, Yas Clinic Khalifa City, Abu Dhabi
January 2022 – September 2023
Chief Medical Officer,
Amiens University Hospital
2019-2025
Senior Consultant Neurologist, Professor of Neurology, Medical Director,
Amiens University Hospital, University of Picardie Jules Verne, France
September 2007 – September 2019
Consultant Neurologist,
University Hospital of Lille, France
November 1999 – September 2007
Specialist Registrar, Department of Neurology & Movement Disorders,
University Hospital of Lille, France
November 1997 – November 1999
PUBLICATIONS
Trial of Lixisenatide in Early Parkinson’s Disease.
Meissner WG, Remy P, Giordana C, Maltête D, Derkinderen P, Houéto JL, Anheim M, Benatru I, Boraud T, Brefel-Courbon C, Carrière N, Catala H, Colin O, Corvol JC, Damier P, Dellapina E, Devos D, Drapier S, Fabbri M, Ferrier V, Foubert-Samier A, Frismand-Kryloff S, Georget A, Germain C, Grimaldi S, Hardy C, Hopes L, Krystkowiak P, Laurens B, Lefaucheur R, Mariani LL, Marques A, Marse C, Ory-Magne F, Rigalleau V, Salhi H, Saubion A, Stott SRW, Thalamas C, Thiriez C, Tir M, Wyse RK, Benard A, Rascol O; LIXIPARK Study Group.N Engl J Med. 2024 Apr 4;390(13):1176-1185.
Trial of Botulinum Toxin for Isolated or Essential Head Tremor.
Marques A, Pereira B, Simonetta-Moreau M, Castelnovo G, De Verdal M, Fluchère F, Laurencin C, Degos B, Tir M, Kreisler A, Blanchet-Fourcade G, Guehl D, Colin O, Poujois A, Sangla S, Tatu L, Derost P, Gayraud D, Tranchant C, Amarantini D, Devos D, Rascol O, Corvol JC, Durif F, Rieu I; Btx-HT Study Group (Krystkowiak P).N Engl J Med. 2023 Nov 9;389(19):1753-1765.
INDUSTRY MEMBERSHIPS
Member of the American Academy of Neurology
Member of the Movement Disorders Society, the International Association for Parkinson's disease and Related Disorders
